Updated On: 08 January, 2021 12:00 AM IST | Mumbai | IANS
According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19

Picture used for representational purpose only
Days after getting Drugs Controller General of India's (DCGI) nod for India's first indigenously-made coronavirus vaccine, Bharat Biotech has again knocked on the doors of the drug controller seeking permission to conduct clinical trials of their intranasal vaccine for the viral disease.
Hyderabad-based Bharat Biotech has applied to the DGCI for permission to start Phase 1 and 2 trials of their nasal coronavirus vaccine, top sources privy to the development told IANS.